AdaptHealth price target raised to $14 from $13 at Canaccord

Canaccord analyst Richard Close raised the firm’s price target on AdaptHealth (AHCO) to $14 from $13 and keeps a Buy rating on the shares. The firm said 4Q was a step forward in rebuilding investor confidence for Adapt as results showed revenue upside and 2025 guidance that has revenue and adj-EBITDA ranges bracketing both Canaccord and consensus prior estimates, and a respectable FCF range of $180-$220 million.